UBS starts coverage of Wave Life Sciences stock with USD 11 target

Published on 10/15/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wave Life Sciences stock costs EUR 2.77 on October 15, 2026. Q2 2026 revenue was USD 2.27 million versus USD 7.45 million expected.

Coverage, results and shareholder dates

UBS began coverage with a USD 11.00 target on October 14, 2026.
Second-quarter 2026 revenue was USD 2.27 million versus USD 7.45 million expected.
Wave Life Sciences stock trades at EUR 2.77 at 12:57 p.m. CEST at Lang & Schwarz on October 15, 2026.

WVE, US94352A1043, Illustration mit AI erstellt.

Wave Life Sciences (ISIN US94352A1043) stock was at EUR 2.77 at Lang & Schwarz on October 15, 2026 at 12:57 p.m. CEST. According to Markets Insider on October 14, 2026, UBS began coverage with a Buy rating and a USD 11.00 price target.

UBS sets a USD 11.00 target

The new target sits below the USD 19.54 consensus target cited in the same report, giving investors a concrete measure of how widely expectations differ. UBS highlighted Wave's RNA editing pipeline and its lead WVE-006 program for alpha-1-antitrypsin deficiency.

The latest reported quarter remains an important counterweight. Wave generated USD 2.27 million of revenue in the second quarter of 2026 and posted a GAAP net loss of USD 69.36 million, according to Markets Insider. Revenue was USD 8.70 million in the year-earlier quarter, while the loss was USD 50.47 million.

Three coverage dates in October

On October 1, 2026, Ladenburg Thalmann initiated coverage with a Buy rating and a USD 10.00 target, as reported by Markets Insider. On October 2, 2026, H.C. Wainwright reiterated a Buy rating and a USD 13.00 target, according to Investing.com. UBS followed on October 14 with its USD 11.00 target.

What dates matter next?

The next substantiated shareholder date is November 12, 2026, when Wave Life Sciences plans to hold its annual meeting. The proxy statement lists four proposals, including the election of nine directors and an increase of 11,000,000 shares available under the 2021 Equity Incentive Plan, according to StockTitan.

RNA pipeline remains central

Wave is a clinical-stage biotechnology company developing RNA medicines for genetic and other serious diseases. The market is weighing that development platform against the second-quarter revenue decline and the competing analyst targets, with the company preparing for a shareholder vote after its August 7, 2026 redomiciliation.

Wave Life Sciences stock was trading at EUR 2.77 at Lang & Schwarz on October 15, 2026 at 12:57 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Wave Life Sciences stock.